congress
presentations
Psychiatry Update (Medscape) 2024
Chicago, IL
June 20-22, 2024
AXS-05 | Major Depressive Disorder
Real-World Auvelity® (AXS-05) Patient Characteristics in Major Depressive Disorder
AXS-05 | Major Depressive Disorder
Dr. Andrew Muzyk, PharmD describes the “Real-World Auvelity® (AXS-05) Patient Characteristics in Major Depressive Disorder”
AXS-05 | Major Depressive Disorder
Efficacy, Tolerability, and Safety of AXS-05, a Novel Oral Antidepressant: Data from 3 Clinical Trials
AXS-05 | Alzheimer’s Disease Agitation
Clinical Profile of AXS-05 (Dextromethorphan-Bupropion) in Treating Alzheimer’s Disease Agitation: Results From The Phase 2/3 Development Program
AXS-05 | Alzheimer’s Disease Agitation
Dr. Jeffrey L. Cummings, MD, ScD describes the “Clinical Profile of AXS-05 (Dextromethorphan-Bupropion) in Treating Alzheimer’s Disease Agitation: Results From The Phase 2/3 Development Program”
AXS-05 | Major Depressive Disorder
Effects of AXS-05 (Dextromethorphan-Bupropion) in Improving Anhedonia and Interest-Activity Symptoms of MDD and the Associated Improvements in Functional Impairment
AXS-05 | Major Depressive Disorder